

## Asarina Pharma AB announces new date for the release of Annual Report for 2023

**Asarina Pharma AB (publ) ("the Company") announces today that the Board has decided to postpone the release of the Annual Report for 2023 to June 4th, 2024.**

The release is postponed as the Company is still working with its auditors to resolve the last outstanding points in the Annual Report.

For additional information, please contact:

Jakob Dynnes Hansen, CFO, Asarina Pharma AB

Telefon: +45 5132 3698

E-post: [jakob.dynnes@asarinapharma.com](mailto:jakob.dynnes@asarinapharma.com)

The Company's Certified Adviser is Carnegie Investment Bank AB (publ).

**For further information, please contact:**

Peter Nordkild, CEO, Asarina Pharma AB

Phone: +45 25 47 16 46

E-mail: [peter.nordkild@asarinapharma.com](mailto:peter.nordkild@asarinapharma.com)

Jakob Dynnes Hansen, CFO, Asarina Pharma AB

Tel: +45 5132 3698

E-mail: [jakob.dynnes@asarinapharma.com](mailto:jakob.dynnes@asarinapharma.com)

The Company's Certified Adviser is Carnegie Investment Bank AB (publ)

**About Asarina Pharma**

Asarina Pharma is a Swedish biotech company developing Sepranolone for allopregnanolone-induced stress- and compulsivity-driven disorders. Our product pipeline is built on over 40 years of research into allopregnanolone-related neurological disorders. With our new family of GAMSAs compounds (GABA-A Modulating Steroid Antagonists) we aim to deliver a new generation of safe, efficacious drugs for neurological conditions from Tourette syndrome to Obsessive Compulsive Disorder that still lack safe, efficacious pharmaceutical treatments.

**Attachments**

[Asarina Pharma AB announces new date for the release of Annual Report for 2023](#)